Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma

American Journal of Surgery

Volumn 207, Issue 4, 2014, Pages 549-554

  Baker, Justin J ^a   Meyers, Michael O ^a   Frank, Jill ^a   Amos, Keith D ^a   Stitzenberg, Karyn B ^a   Ollila, David W ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Melanoma; Recurrence; Restaging

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGED; ARM; ARTICLE; ASYMPTOMATIC DISEASE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CUTANEOUS MELANOMA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MITOSIS RATE; NECK; NUCLEAR MAGNETIC RESONANCE IMAGING; PET-CT SCANNER; PHYSICIAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE; TRUNK; VERY ELDERLY; YOUNG ADULT;

MELANOMA; RECURRENCE; RESTAGING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; YOUNG ADULT;

EID: 84896987510     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2013.04.012     Document Type: Article

References (31)

1. Surveillance, Epidemiology and End Results data from the National Cancer Institute. http://www.seer.cancer.gov. Accessed February 8, 2011.
2. R. Siegel, E. Ward, and O. Brawley et al. Cancer statistics 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 2011 212 236
3. C.M. Balch, J.E. Gershenwald, and S.J. Soong et al. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
4. J.E. Gershenwald, S.J. Soong, and C.M. Balch 2010 TNM staging system for cutaneous melanoma...and beyond Ann Surg Oncol 17 2010 1475 1477
5. D.L. Morton, J.F. Thompson, and A.J. Cochran et al. Sentinel-node biopsy or nodal observation in melanoma N Engl J Med 355 2006 1307 1317
6. J.R. Marsden, J.A. Newton-Bishop, and L. Burrows et al. Revised UK guidelines for the management of cutaneous melanoma 2010 J Plast Reconstr Aesthet Surg 63 2010 1401 1419
7. C. Garbe, A. Hauschild, and M. Volkenandt et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma Melanoma Res 17 2007 393 399
8. NCCN guidelines. http://www.nccn.org. Accessed February 8, 2011.
9. M.O. Meyers, J.J. Yeh, and J. Frank et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging Ann Surg Oncol 16 2009 941 947
10. A.B. Francken, H.M. Shaw, and N.A. Accortt et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines Ann Surg Oncol 14 2007 1924 1933
11. E. Romano, M. Scordo, and S.W. Dusza et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines J Clin Oncol 28 2010 3042 3047
12. U. Hofmann, M. Szedlak, and W. Rittgen et al. Primary staging and follow-up in melanoma patients - monocenter evaluation of methods, costs and patient survival Br J Cancer 87 2002 151 157
13. C. Garbe, A. Paul, and H. Kohler-Spath et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy J Clin Oncol 21 2003 520 529
14. D.L. Morton, N. Mozzillo, J.F. Thompson MMAIT Clinical Trials Group An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites J Clin Oncol 25 2007 8508
15. D.W. Ollila A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430 Cancer 117 2011 4579 4581
16. J.A. Sosman, J. Moon, and R.J. Tuthill et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430 Cancer 117 2011 4740 4746
17. C. Robert, L. Thomas, and I. Bondarenko et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
18. P.B. Chapman, A. Hauschild, and C. Robert et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
19. G.C. Alvarado, N.E. Papadopoulos, and W.J. Hwu et al. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck Melanoma Res 21 2011 127 130
20. T.S. Aukema, R.A. Olmos, and C.M. Korse et al. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up Ann Surg Oncol 17 2010 1657 1661
21. A.B. Francken, and H.J. Hoekstra Follow-up of melanoma patients: the need for evidence-based protocols Ann Surg Oncol 16 2009 804 805
22. A. Klingenstein, A.R. Haug, and M.M. Nentwich et al. Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma Melanoma Res 20 2010 511 516
23. I.O. Koskivuo, M.P. Seppanen, and E.A. Suominen et al. Whole body positron emission tomography in follow-up of high risk melanoma Acta Oncol 46 2007 685 690
24. R.L. Morton, J.C. Craig, and J.F. Thompson The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients Ann Surg Oncol 16 2009 571 577
25. Y. Xing, Y. Bronstein, and M.I. Ross et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis J Natl Cancer Inst 103 2011 129 142
26. K. Strobel, R. Dummer, and H.C. Steinert et al. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B Eur J Nucl Med Mol Imaging 35 2008 1786 1795
27. C. Akcali, S. Zincirkeser, and Z. Erbagcy et al. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT J Int Med Res 35 2007 547 553
28. M.O. Meyers, J.J. Yeh, and K.D. Amos et al. Utility of routine PET/CT and MRI staging in patients with sentinel lymph node positive melanoma J Clin Oncol 27 2009 9071
29. T. Wagner, N. Meyer, and S. Zerdoud et al. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node Br J Dermatol 164 2011 1235 1240
30. J. Horn, J. Lock-Andersen, and H. Sjostrand et al. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy Eur J Nucl Med Mol Imaging 33 2006 887 892
31. K. Strobel, R. Dummer, and D.B. Husarik et al. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases Radiology 244 2007 566 574